



**FLORIDA SOCIETY OF CLINICAL ONCOLOGY FAX BLAST –June 24, 2009**

**FLASCO WEBSITE: [www.flasco.org](http://www.flasco.org)**

**FLASCO CLINICAL TRIALS NETWORK WEBSITE: [www.fctn.org](http://www.fctn.org)**

**MESSAGE FROM THE PRESIDENT: Gerald Robbins, MD**

Congratulations to FLASCO Affiliate member **David A. Johnson, PA-C** on being elected to the Presidency for the National Association of PAs in Oncology. Mr. Johnson is Department Chair, Advanced Practice Professionals, Midlevel Education Coordinator, Sarcoma Program at the Moffitt Cancer Center.

**LEGISLATIVE UPDATE: Erin Dunbar, MD, Chairman – Scott Tetreault, MD, Vice Chairman**

**COA is asking you to** join your colleagues in Washington, DC on July 8th to walk the halls of Capitol Hill to *Stand Up for Cancer Care*. To register for this event please contact: [dshook@COAcancer.org](mailto:dshook@COAcancer.org)

If you have never done this before, do not worry. A full agenda will be provided to you upon arrival in DC, including appointments scheduled on your behalf with your individual representatives, training, maps and leave-behind materials. COA is asking that **all registrations be completed ASAP** so as to allow them time to schedule appointments with your congressional members. If you have any questions, please contact Dee Shook <[dshook@COAcancer.org](mailto:dshook@COAcancer.org)> or you may **Phone: 202-756-2258**

**Invite your US House Member and US Senator to your practice:**

It is extremely important for all FLASCO Members to be actively involved in Healthcare Reform. We need to let our voices be heard.

Please invite your US Congressman and our two US Senators to visit your practice – let them see what you are facing each day in your practice (whether it be a private practice or academic practice). Let them know what you believe is needed to provide quality healthcare to our cancer patients in Florida.

Congress will be in recess during the month of August – a great time to invite them to your practice. **Please start inviting them to visit your practice NOW.**

**PROGRAM COMMITTEE UPDATES:**

FLASCO will be holding its 1<sup>st</sup> Annual Business of Oncology Summit on October 3, 2009. FLASCO has partnered with Abraxis BioScience to hold this very exciting and timely conference. Topics that will be presented by expert speakers are as follows: Financial Planning, Managed Care Contract Negotiations, Succession Planning, Clinical Pathway Development and Implementation, Utilizations and Responsibilities of the PA/ARNP, and Strategic Planning: What, Why and How.

JOIN US for this professional forum that explores what cancer care leaders are doing to achieve a future vision of successful cancer care delivery, focusing on innovative business practices, clinical integration, and patient-centric approaches to providing care. For more information on the Business of Oncology Summit or to register, please go online to [www.flasco.org](http://www.flasco.org). The meeting announcement and registration form are available there.

**FCSO UPDATES:**

**J9999: Plerixafor (MOZOBIL™) -- revision to article**

Plerixafor (MOZOBIL™) is a hematopoietic stem cell mobilizer that was approved by the Food and Drug Administration (FDA) on December 15, 2008. It is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to

mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. The recommended dosage and administration protocol for MOZOBIL™ is to initiate MOZOBIL™ after the patient has received G-CSF once daily for 4 days. The dose is selected based on 0.24mg/kg actual body weight and is administered by subcutaneous injection approximately 11 hours prior to apheresis. MOZOBIL™ may be repeated up to 4 consecutive days. MOZOBIL™ may be billed to the Medicare contractor with HCPCS codes J3490 (Unclassified drugs) or J9999 (Not otherwise classified, antineoplastic drugs) or effective for dates of service on or after July 1, 2009, may be billed with HCPCS code C9252 (Injection, plerixafor, 1 mg). In addition, the list of ICD-9-CM codes that First Coast Service Options Inc. (FCSO) will consider as medically reasonable and necessary has been expanded to include all of the following: 200.00-200.08, 200.10-200.18, 200.20-200.28, 200.30-200.38, 200.40-200.48, 200.50-200.58, 200.60-200.68, 200.70-200.78, 200.80-200.88, 202.00-202.08, 202.10-202.18, 202.20-202.28, 202.30-202.38, 202.40-202.48, 202.50-202.58, 202.60-202.68, 202.70-202.78, 202.80-202.88, 202.90-202.98, 203.00 and 203.01.

At this time, the only G-CSF that FCSO recognizes as medically reasonable and necessary to be used in combination with MOZOBIL™ therapy is filgrastim (Neupogen®), HCPCS code J1440 or J1441. The G-CSF would be administered via subcutaneous bolus or continuous infusion once daily in the morning for 4 days prior to the first evening dose of MOZOBIL™. FCSO would not expect to see any chemotherapy drugs billed on the same day that Neupogen® is being administered for this course of therapy. In addition, all coverage requirements for Neupogen® outlined in the local coverage determination (LCD) for Neupogen® would still apply, including indications and limitations of coverage, ICD-9-CM codes that support medical necessity, utilization guidelines and documentation guidelines. The LCD for Neupogen® can be located at <http://medicare.fcsso.com>.

[http://medicare.fcsso.com/Coverage\\_News/151370.asp](http://medicare.fcsso.com/Coverage_News/151370.asp)

## **ASCO UPDATES**

### **ASCO announces Breast Cancer Registry Pilot Program**

ASCO is pleased to announce the ASCO Breast Cancer Registry Pilot Program, funded by Susan G. Komen for the Cure. The program expands upon ASCO's current quality initiatives, combining strategies to improve care coordination and communication with data-informed practice improvement. The Registry Pilot will provide outpatient oncology practices with an innovative, web-based application that will allow for submission of clinical and treatment information at the point of care. For more information about the application requirements and process, visit [www.asco.org/BCR](http://www.asco.org/BCR)

## **PA/NP UPDATES:**

### **12<sup>th</sup> Annual APAO Conference**

The APAO National Conference is scheduled for September 10-13, 2009, in Boston. The meeting is for MidLevels and Physicians. There will be an ASCO highlights on 9/10/09. You may register on-line at: <http://www.focus-ed.net/apao/>

## **EDUCATIONAL OPPORTUNITIES**

### **Bristol Myers Squibb – Development in Chronic Leukemia – on demand conference**

This 24 hour a day on-demand conference features Michael J. Mauro, MD. To participate, please type in the following URL address: <http://developmentsincml.com> – please complete the registration page and when prompted, please enter the following password: **ondemand**.

**Roche** would like to extend the offer for FLASCO members to participate in an educational webcast series, updating you on current issues affecting the management of Colorectal Cancer (CRC). There is free CME course for physicians.

Information on the Webcasts as follows:

Educational Intervention 1

Webcast 1: Individualized Therapy for Colorectal Cancer: Ready for Prime Time?

Available NOW!!

Educational Interventions 2 and 3

Webcast 3: A post-ASCO Webcast continuation - Available July 2009

Educational Intervention 4

Webcast 4: Performance Measures: Trying It All Together - Available October 2009

To register for these webcasts or to view the presentation, please go to [www.meddigest.com/CRC](http://www.meddigest.com/CRC)

**BUSINESS Q & A: (Source: The Phipps Wealth Management Group)**

- Q. I get the feeling that my malpractice litigation is going to be on the increase.....many patients are desperate and they see my “deep pockets”. What can I do to anticipate this?
- A. Assuming you have the requisite \$250,000/\$750,000 malpractice insurance coverage and are not *bare*, here are four assets that are protected (as a Florida resident): your homestead, life insurance, variable annuities and qualified retirement plans.

When we do a financial **H & P** for our new clients, we allocate an inordinate amount of time to asset/income protection.

For more information you may contact: 561-276-1635 Direct - 877-276-1635 Toll Free – fax: 561-922-3275 - E-mail: [jeffrey\\_phippsr@ml.com](mailto:jeffrey_phippsr@ml.com) - <http://fa.ml.com/PhippsGroup/>

**CORPORATE MEMBERSHIP/SPONSORSHIP: (January 1 – December 31, 2009)**

FLASCO Members extend a big thanks to all of our 2009 Corporate Members/Sponsors (Companies listed below have either paid 2009 dues or have submitted letters of intent)

**PLATINUM**

AMGEN  
Bayer/Onyx  
Cephalon Oncology  
Eli Lilly  
Oncology Supply/ION  
Sanofi-Aventis  
Celgene  
Eisai, Inc.  
Ortho Biotech  
Genentech  
GlaxoSmithKline  
The Phipps Wealth  
Management Group  
Novartis  
Astra Zeneca  
Pfizer

**GOLD**

Abraxis Oncology  
Bristol Myers Squibb  
Genomic Health  
Wyeth  
Roche  
Millennium

**SILVER**

OSI Pharmaceuticals  
US Oncology

**BRONZE**

Genzyme

**FLASCO 2009 MEETINGS:**

**October 3, 2009** – FLASCO Business of Oncology Summit - Tampa

**November 6-7, 2009** – FLASCO Fall Meeting – Tampa Airport Marriott Hotel

**March 5-6, 2010** – FLASCO Spring Meeting and Annual Session – Tampa Airport Marriott Hotel

**OTHER MEETINGS/WEBCASTS**

**September 10-13, 2009** APAO Annual meeting in Boston

**September 22-25, 2009** - ACCC's 26th National Oncology Economics Conference - - Hyatt Regency Minneapolis on Nicollet Mall, 1300 Nicollet Mall, Minneapolis, MN 55403 - 612.370.1234

**March 17-20, 2010** - ACCC's 36th Annual National Meeting - -Baltimore Marriott Waterfront  
700 Aliceanna Street, Baltimore, MD 21202 - 410.385.3000